# Medical Developments International buys back EU rights to Penthrox inhaler from Mundipharma

Medical Developments International (MVP) will buy back the European Union rights to its Penthrox methoxyflurane inhaler from Mundipharma for €3 million, plus a 5% royalty up to a maximum of €5 million. A 6-month transition period begins September 1, 2020.

- Type: Acquisition
- Announced: 2020-08-01
- Value: $3.54M (3.00M EUR)
- Status: announced
- Products: Penthrox methoxyflurane inhaler
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Mundipharma](https://endata.com/companies/35563.md) (target)
- [Medical Developments International](https://endata.com/companies/49043.md) (acquirer)

## Sources

- [oindpnews.com](https://www.oindpnews.com/2020/08/medical-developments-international-buys-back-european-union-rights-to-penthrox-inhaler-from-mundipharma/), 2020-08-01: "Medical Developments International (MVP) has announced that it will buy back the European Union rights to its Penthrox methoxyflurane inhaler from Mundipharma for €3 million, plus a 5% royalty up to a maximum of €5 million."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.